

Table 14-6.05

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		p-value
Shift		Normal at	High at	Normal at	High at	Normal at	High at	
[1]		Baseline	Baseline	Baseline	Baseline	Baseline	Baseline	[2]
CHEMISTRY								

ALANINE AMINOTRANSFERASE	n	82	2	79	1	80	0	0.828
	Normal	80 (98%)	0	78 (99%)	0	78 (98%)	0	
	High	2 (2%)	2 (100%)	1 (1%)	1 (100%)	2 (2%)	0	
ALBUMIN	n	84	0	80	0	80	0	0.611
	Normal	84 (100%)	0	80 (100%)	0	80 (100%)	0	
	High	0	0	0	0	0	0	
ALKALINE PHOSPHATASE	n	82	2	79	0	79	1	0.770
	Normal	81 (99%)	0	78 (99%)	0	79 (100%)	0	
	High	1 (1%)	2 (100%)	1 (1%)	0	0	1 (100%)	
ASPARTATE AMINOTRANSFERASE	n	82	2	79	1	80	0	0.770
	Normal	79 (96%)	1 (50%)	77 (97%)	1 (100%)	78 (98%)	0	
	High	3 (4%)	1 (50%)	2 (3%)	0	2 (2%)	0	
BILIRUBIN	n	84	0	79	0	79	1	0.770
	Normal	83 (99%)	0	79 (100%)	0	77 (97%)	0	
	High	1 (1%)	0	0	0	2 (3%)	1 (100%)	
CALCIUM	n	84	0	80	0	80	0	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

[1] A subject is counted only once for each analyte. A change will be considered shifting from normal at baseline to abnormal or from abnormal at baseline to normal at any visit during the treatment. The treatment period is defined as any planned visit after Week 0 (Visit 3), up to and including Week 24 (Visit 12).

[2] CMH test for general association, controlling for status at baseline.

Source: programs/t-14-6.05.R

19:31 Tuesday, June 16, 2020

Table 14-6.05

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		p-value
Shift		Normal at	High at	Normal at	High at	Normal at	High at	
[1]		Baseline	Baseline	Baseline	Baseline	Baseline	Baseline	[2]
CHLORIDE	Normal	84 (100%)	0	80 (100%)	0	80 (100%)	0	
	n	84	0	80	0	79	0	
CHOLESTEROL	Normal	84 (100%)	0	80 (100%)	0	79 (100%)	0	
	n	84	0	80	0	80	0	
CREATINE KINASE	Normal	84 (100%)	0	80 (100%)	0	80 (100%)	0	0.811
	n	84	0	79	1	77	3	
	Normal	77 (92%)	0	74 (94%)	1 (100%)	72 (94%)	1 (33%)	
CREATININE	High	7 (8%)	0	5 (6%)	0	5 (6%)	2 (67%)	
	n	84	0	80	0	80	0	
	Normal	84 (100%)	0	80 (100%)	0	80 (100%)	0	
GAMMA GLUTAMYL TRANSFERASE	n	82	2	78	2	78	2	0.898
	Normal	80 (98%)	0	75 (96%)	1 (50%)	76 (97%)	1 (50%)	
	High	2 (2%)	2 (100%)	3 (4%)	1 (50%)	2 (3%)	1 (50%)	
GLUCOSE	n	83	1	80	0	80	0	
	Normal	83 (100%)	1 (100%)	79 (99%)	0	78 (98%)	0	
	High	0	0	1 (1%)	0	2 (2%)	0	
PHOSPHATE	n	84	0	79	0	80	0	
	Normal	84 (100%)	0	79 (100%)	0	80 (100%)	0	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

[1] A subject is counted only once for each analyte. A change will be considered shifting from normal at baseline to abnormal or from abnormal at baseline to normal at any visit during the treatment. The treatment period is defined as any planned visit after Week 0 (Visit 3), up to and including Week 24 (Visit 12).

[2] CMH test for general association, controlling for status at baseline.

Source: programs/t-14-6.05.R

19:31 Tuesday, June 16, 2020

Table 14-6.05

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		
	Shift	Normal at	High at	Normal at	High at	Normal at	High at	p-value
	[1]	Baseline	Baseline	Baseline	Baseline	Baseline	Baseline	[2]
POTASSIUM	n	84	0	79	0	79	0	0.363
	Normal	84 (100%)	0	79 (100%)	0	79 (100%)	0	
PROTEIN	n	84	0	80	0	80	0	
	Normal	84 (100%)	0	80 (100%)	0	80 (100%)	0	
SODIUM	n	84	0	80	0	79	0	
	Normal	84 (100%)	0	80 (100%)	0	79 (100%)	0	
URATE	n	84	0	80	0	80	0	
	Normal	84 (100%)	0	80 (100%)	0	80 (100%)	0	
UREA NITROGEN	n	84	0	78	2	80	0	
	Normal	84 (100%)	0	78 (100%)	2 (100%)	79 (99%)	0	
	High	0	0	0	0	1 (1%)	0	
HEMATOLOGY								

BASOPHILS	n	83	0	79	0	78	0	
	Normal	83 (100%)	0	79 (100%)	0	78 (100%)	0	
EOSINOPHILS	n	83	0	78	1	78	0	
	Normal	83 (100%)	0	73 (94%)	1 (100%)	72 (92%)	0	
	High	0	0	5 (6%)	0	6 (8%)	0	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

[1] A subject is counted only once for each analyte. A change will be considered shifting from normal at baseline to abnormal or from abnormal at baseline to normal at any visit during the treatment. The treatment period is defined as any planned visit after Week 0 (Visit 3), up to and including Week 24 (Visit 12).

[2] CMH test for general association, controlling for status at baseline.

Source: programs/t-14-6.05.R

19:31 Tuesday, June 16, 2020

Table 14-6.05

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		p-value
Shift		Normal at	High at	Normal at	High at	Normal at	High at	
[1]		Baseline	Baseline	Baseline	Baseline	Baseline	Baseline	[2]
ERY. MEAN CORPUSCULAR HB CONCENTRATION	n	82	0	78	0	77	0	
	Normal	82 (100%)	0	78 (100%)	0	77 (100%)	0	
ERY. MEAN CORPUSCULAR HEMOGLOBIN	n	83	0	79	0	78	0	
	Normal	83 (100%)	0	79 (100%)	0	78 (100%)	0	
ERY. MEAN CORPUSCULAR VOLUME	n	82	0	78	0	77	0	
	Normal	82 (100%)	0	78 (100%)	0	77 (100%)	0	
ERYTHROCYTES	n	83	0	79	0	78	0	
	Normal	83 (100%)	0	79 (100%)	0	78 (100%)	0	
HEMATOCRIT	n	82	0	78	0	77	0	
	Normal	82 (100%)	0	78 (100%)	0	77 (100%)	0	
HEMOGLOBIN	n	83	0	79	0	78	0	
	Normal	83 (100%)	0	79 (100%)	0	78 (100%)	0	
LEUKOCYTES	n	83	0	79	0	78	0	
	Normal	83 (100%)	0	79 (100%)	0	78 (100%)	0	
LYMPHOCYTES	n	83	0	79	0	78	0	
	Normal	82 (99%)	0	79 (100%)	0	78 (100%)	0	
	High	1 (1%)	0	0	0	0	0	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

[1] A subject is counted only once for each analyte. A change will be considered shifting from normal at baseline to abnormal or from abnormal at baseline to normal at any visit during the treatment. The treatment period is defined as any planned visit after Week 0 (Visit 3), up to and including Week 24 (Visit 12).

[2] CMH test for general association, controlling for status at baseline.

Source: programs/t-14-6.05.R

19:31 Tuesday, June 16, 2020

Table 14-6.05

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		p-value
Shift		Normal at	High at	Normal at	High at	Normal at	High at	
[1]		Baseline	Baseline	Baseline	Baseline	Baseline	Baseline	[2]
MONOCYTES	n	81	0	79	0	78	0	
	Normal	81 (100%)	0	79 (100%)	0	78 (100%)	0	
PLATELET	n	83	0	77	0	78	0	
	Normal	83 (100%)	0	77 (100%)	0	78 (100%)	0	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

[1] A subject is counted only once for each analyte. A change will be considered shifting from normal at baseline to abnormal or from abnormal at baseline to normal at any visit during the treatment. The treatment period is defined as any planned visit after Week 0 (Visit 3), up to and including Week 24 (Visit 12).

[2] CMH test for general association, controlling for status at baseline.

Source: programs/t-14-6.05.R

19:31 Tuesday, June 16, 2020